Future Light Ventures
Investing in the teams that are improving, developing, and adding value to the human experience
The manner of how we better the human condition and our quality of life has shifted. The maturation of this $1.5 trillion sector is accelerating and the next generation has taken the responsibility of pushing the limits of exploring treatments, services, and technology.
We shine a light on the entrepreneur shaping tomorrow, and companies whose products and services challenge stigmas and bring health, joy, and dignity to humankind.
We invest in early stage technologies across disruptive heavily regulated sectors including Mental Health, Novel Substances, DeathTech, FemTech, and Psychedelics. Areas where regulations are rapidly evolving and social norms are changing.
Hand on experience at every level of the supply chain.
Unique European deal flow from team members respected as pioneers in the region and advisors from the European Commission.
Healthcare operators and expertise with US and European experience in mental and neurological health
Product development and innovation of new medicines and applications
Venture capital and corporate finance experience investing in cannabis, technology, and healthcare
Retail development in three states US states with more than 30 locations
Cannabis design and development of new genetics and phenotypes in North America and equatorial regions
Lobbying and composition of legislation in European countries introducing alternative wellness
A team with over 30 years of combined operational experience in heavily regulated industries with the knowledge to enter with the lucrative international market with proficiency. The Future Light Ventures team has the unique ability to improve, develop, and add value to any level of the supply chain and leverage the challenges they faced in with traditional healthcare
Jason Sydney has developed manufacturing facilities and distribution centers in Humboldt, California and is an owner of the Humboldt Brand Cannabis Company). He has invested in cannabis operations throughout North America while at Blue Dream Capital. He has consulted for international cannabis operations in Rwanda, Montenegro, and Jamaica. Jason sits on the board for NORDx and is an alumnus of London School of Economics, HEC Paris, and NYU.
Co-founder of The Hanway Company drug policy venture studio and Hanway Associates cannabis advisory firm. He co-founded a psychedelic clinical research organization, Clerkenwell Health in 2021. He was co-founder and Managing Director of Cannabis Europa (exited 2019) and Creative Director at Volteface, the UK's first cannabis policy think tank.
Maxim has specialized in development and design of retail cannabis assets, M&A, technology implementation, and built one of the largest vertically integrated retail operations in his home state, Michigan. He has opened 20 retail locations in the United States.
Extensive experience in the areas of mergers and acquisitions, private equity and venture capital, joint ventures, corporate governance and general corporate law. He regularly advises cannabis and hemp businesses in navigating the intersection between state and federal law, general business representation, licensing, investment, regulatory compliance and intellectual property
Crain’s Detroit Business Notable Women in Manufacturing (2019), National Association of Women Business Owners Top Ten Women in Global Business (2014).
Derivatives transaction counsel at Goldman Sachs in London, before becoming an Executive Director in the Investment Management Division. Management at Europe’s crisis fund in Luxembourg.